A study to learn if nirogacestat works and is safe for adult participants with desmoid tumors: a plain language summary of the DeFi study.
作者信息
Kasper Bernd, Whiting Jeanne, Lawson Dana, Portnoy Marlene, Schuster Kathrin, Baumgarten Christina, Ratan Ravin, Lim Allison, Cho Sunny, Kummar Shivaani, Gounder Mrinal
机构信息
aUniversity of Heidelberg, Mannheim University Medical Center, Mannheim Cancer Center, Sarcoma Unit, Mannheim, Germany.
bThe Desmoid Tumor Research Foundation, USA.
出版信息
Future Oncol. 2025 Apr;21(8):889-901. doi: 10.1080/14796694.2025.2462519. Epub 2025 Mar 12.
Abstract
摘要
相似文献
1
A study to learn if nirogacestat works and is safe for adult participants with desmoid tumors: a plain language summary of the DeFi study.一项关于尼罗加司他对成人硬纤维瘤患者是否有效及安全的研究：DeFi研究的通俗易懂总结。
Future Oncol. 2025 Apr;21(8):889-901. doi: 10.1080/14796694.2025.2462519. Epub 2025 Mar 12.
2
Nirogacestat-the pathway to approval of the first treatment for desmoid tumors, a rare disease.尼洛妥昔单抗——治疗韧带样型纤维瘤病（一种罕见疾病）的首款疗法获批之路。
Ther Adv Rare Dis. 2025 Feb 11;6:26330040251317546. doi: 10.1177/26330040251317546. eCollection 2025 Jan-Dec.
3
Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors.尼拉格塞特，一种针对硬纤维瘤的γ-分泌酶抑制剂。
N Engl J Med. 2023 Mar 9;388(10):898-912. doi: 10.1056/NEJMoa2210140.
4
Onset and resolution of ovarian toxicity with nirogacestat treatment in females with desmoid tumors: Updated safety analyses from the DeFi phase 3 study.尼拉格塞特治疗女性硬纤维瘤的卵巢毒性的发生和消退：DeFi 期 3 研究的更新安全性分析。
Cancer. 2024 Aug 15;130(16):2812-2821. doi: 10.1002/cncr.35324. Epub 2024 May 4.
5
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial.PRIMA试验中一线卵巢癌患者使用尼拉帕利维持治疗时的无疾病或毒性症状的质量调整时间以及质量调整无进展生存期。
Ther Adv Med Oncol. 2022 Sep 22;14:17588359221126149. doi: 10.1177/17588359221126149. eCollection 2022.
6
Examining nirogacestat for adults with progressing desmoid tumors who require systemic treatment.检查尼拉戈塞特用于需要全身治疗的进展性硬纤维瘤成人患者。
Expert Opin Pharmacother. 2024 Nov;25(16):2115-2124. doi: 10.1080/14656566.2024.2418416. Epub 2024 Oct 18.
7
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区，服用抗叶酸抗疟药物的人群中，叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
8
Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma.talquetamab用于复发或难治性多发性骨髓瘤患者的MonumenTAL-1研究的简明语言摘要。
Future Oncol. 2023 Sep;19(27):1823-1840. doi: 10.2217/fon-2023-0332. Epub 2023 Jul 26.
9
Low-dose titrated amitriptyline as second-line treatment for adults with irritable bowel syndrome in primary care: the ATLANTIS RCT.低剂量滴定阿米替林作为一线治疗对初级保健中成人肠易激综合征的二线治疗：ATLANTIS RCT。
Health Technol Assess. 2024 Oct;28(66):1-161. doi: 10.3310/BFCR7986.
10
GOunder/Desmoid Tumor Research Foundation DEsmoid Symptom/Impact Scale (GODDESS): psychometric properties and clinically meaningful thresholds as assessed in the Phase 3 DeFi randomized controlled clinical trial.GO 下腹部/腹壁纤维瘤研究基金会 DESMOID 症状/影响量表（GODDESS）：在 3 期 DeFi 随机对照临床试验中的心理测量特性和临床有意义的阈值评估。
Qual Life Res. 2023 Oct;32(10):2861-2873. doi: 10.1007/s11136-023-03445-7. Epub 2023 Jun 22.
Zotero 插件